tiprankstipranks

Integra LifeSciences assumed with an Underweight at Morgan Stanley

Morgan Stanley assumed coverage of Integra LifeSciences (IART) with an Underweight rating with a price target of $20, down from $25. The firm maintains concerns regarding the company’s execution against its topline growth and margin expansion initiatives, calling it a “show-me” story.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue